Literature DB >> 9144367

Baculovirus-expressed nonstructural protein NS2 of bluetongue virus induces a cytotoxic T-cell response in mice which affords partial protection.

L D Jones1, T Williams, D Bishop, P Roy.   

Abstract

Virus-specific cytotoxic T lymphocytes were generated in two strains of mice (BALB/c and CBA/Ca) against baculovirus recombinant proteins (minor and nonstructural) derived from bluetongue virus serotype 10. Immunization of mice with recombinant baculovirus insect cell extracts expressing the nonstructural protein NS2 (Bac-NS2) conferred partial protection against infection with vaccinia virus expressing the NS2 protein. This protective immunity was mediated by CD8+ cells. In contrast, no protection was observed when mice were immunized with similarly expressed Bac-NS1 or -NS3 or the virion minor structural proteins (Bac-VP1, -VP4, or -VP6). Furthermore, the in vitro cytotoxicity activity of T cells derived from immunized animals did not correlate to the protective efficacy of baculovirus recombinant proteins. The implications of this work with regard to the design of noninfectious subunit vaccines are discussed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9144367      PMCID: PMC170522          DOI: 10.1128/cdli.4.3.297-301.1997

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  11 in total

1.  Anti-viral protection and prevention of lymphocytic choriomeningitis or of the local footpad swelling reaction in mice by immunization with vaccinia-recombinant virus expressing LCMV-WE nucleoprotein or glycoprotein.

Authors:  M Hany; S Oehen; M Schulz; H Hengartner; M Mackett; D H Bishop; H Overton; R M Zinkernagel
Journal:  Eur J Immunol       Date:  1989-03       Impact factor: 5.532

2.  Epizootiological study of bluetongue virus infection in California livestock: an overview.

Authors:  J L Stott; B I Osburn; R Bushnell; E C Loomis; K R Squire
Journal:  Prog Clin Biol Res       Date:  1985

3.  Assembly of double-shelled, viruslike particles of bluetongue virus by the simultaneous expression of four structural proteins.

Authors:  T J French; J J Marshall; P Roy
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

4.  Use of baculovirus expression vectors: development of diagnostic reagents, vaccines and morphological counterparts of bluetongue virus.

Authors:  P Roy
Journal:  FEMS Microbiol Immunol       Date:  1990-11

5.  Antiviral protection by CD8+ versus CD4+ T cells. CD8+ T cells correlating with cytotoxic activity in vitro are more efficient in antivaccinia virus protection than CD4-dependent IL.

Authors:  D Binder; T M Kündig
Journal:  J Immunol       Date:  1991-06-15       Impact factor: 5.422

6.  Induction of protective cytotoxic T cells with viral proteins.

Authors:  M F Bachmann; T M Kündig; G Freer; Y Li; C Y Kang; D H Bishop; H Hengartner; R M Zinkernagel
Journal:  Eur J Immunol       Date:  1994-09       Impact factor: 5.532

7.  Long-lasting protection of sheep against bluetongue challenge after vaccination with virus-like particles: evidence for homologous and partial heterologous protection.

Authors:  P Roy; D H Bishop; H LeBlois; B J Erasmus
Journal:  Vaccine       Date:  1994-07       Impact factor: 3.641

8.  Characterization of immune responses to baculovirus-expressed equine herpesvirus type 1 glycoproteins D and H in a murine model.

Authors:  D Tewari; J M Whalley; D N Love; H J Field
Journal:  J Gen Virol       Date:  1994-07       Impact factor: 3.891

9.  The non-structural proteins of bluetongue virus are a dominant source of cytotoxic T cell peptide determinants.

Authors:  L D Jones; T Chuma; R Hails; T Williams; P Roy
Journal:  J Gen Virol       Date:  1996-05       Impact factor: 3.891

10.  Primary pulmonary cytotoxic T lymphocytes induced by immunization with a vaccinia virus recombinant expressing influenza A virus nucleoprotein peptide do not protect mice against challenge.

Authors:  C M Lawson; J R Bennink; N P Restifo; J W Yewdell; B R Murphy
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

View more
  6 in total

1.  Purification, stability, and immunogenicity analyses of five bluetongue virus proteins for use in development of a subunit vaccine that allows differentiation of infected from vaccinated animals.

Authors:  Jenna Anderson; Emmanuel Bréard; Karin Lövgren Bengtsson; Kjell-Olov Grönvik; Stéphan Zientara; Jean-Francois Valarcher; Sara Hägglund
Journal:  Clin Vaccine Immunol       Date:  2014-01-22

2.  Evaluation of the immunogenicity of an experimental subunit vaccine that allows differentiation between infected and vaccinated animals against bluetongue virus serotype 8 in cattle.

Authors:  Jenna Anderson; Sara Hägglund; Emmanuel Bréard; Loic Comtet; Karin Lövgren Bengtsson; John Pringle; Stéphan Zientara; Jean Francois Valarcher
Journal:  Clin Vaccine Immunol       Date:  2013-05-29

3.  Oncolytic bluetongue viruses: promise, progress, and perspectives.

Authors:  Joseph K-K Li
Journal:  Front Microbiol       Date:  2011-03-16       Impact factor: 5.640

4.  Immunogenicity of recombinant VP2 proteins of all nine serotypes of African horse sickness virus.

Authors:  Yuta Kanai; Piet A van Rijn; Mieke Maris-Veldhuis; Yuki Kaname; T N Athmaram; Polly Roy
Journal:  Vaccine       Date:  2014-07-18       Impact factor: 3.641

5.  The Combined Expression of the Nonstructural Protein NS1 and the N-Terminal Half of NS2 (NS21-180) by ChAdOx1 and MVA Confers Protection against Clinical Disease in Sheep upon Bluetongue Virus Challenge.

Authors:  Sergio Utrilla-Trigo; Luis Jiménez-Cabello; Eva Calvo-Pinilla; Alejandro Marín-López; Gema Lorenzo; Pedro Sánchez-Cordón; Sandra Moreno; Julio Benavides; Sarah Gilbert; Aitor Nogales; Javier Ortego
Journal:  J Virol       Date:  2021-11-17       Impact factor: 5.103

6.  Establishment of a bluetongue virus infection model in mice that are deficient in the alpha/beta interferon receptor.

Authors:  Eva Calvo-Pinilla; Teresa Rodríguez-Calvo; Juan Anguita; Noemí Sevilla; Javier Ortego
Journal:  PLoS One       Date:  2009-04-09       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.